Floatz logo

FCH

Magnetic Resonance Imaging

National Taiwan University HospitalSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Magnetic Resonance Imaging cohort.

Asset / SponsorPhaseRating
GADOPENTETATE DIMEGLUMINE
National Taiwan University Hospital
Phase 4BB
BAY86-4882
Bayer
Phase 3BB
BAY86-4875
Bayer
Phase 3BB
Gadobutrol
Bayer
Phase 3BB
Iop
MegaPro Biomedical Co. Ltd.
Phase 2B

View all 14 →

Same molecule, other indications

FCH is also rated in:

breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Positron Emission TomographyDormant
BB
Indicative ·
65 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →